Espen Molden
Diakonhjemmet Hospital
Norway
Name/email consistency: high
- Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response. Molden, E., Okkenhaug, C., Ekker Solberg, E. Eur. J. Clin. Pharmacol. (2010)
- High-performance liquid chromatography-mass spectrometry analysis of diltiazem and 11 of its phase I metabolites in human plasma. Molden, E., Helen Bøe, G., Christensen, H., Reubsaet, L. J. Pharm. Biomed. Anal (2003)
- Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4. Molden, E., Asberg, A., Christensen, H. Drug Metab. Dispos. (2002)
- Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. Molden, E., Johansen, P.W., Bøe, G.H., Bergan, S., Christensen, H., Rugstad, H.E., Rootwelt, H., Reubsaet, L., Lehne, G. Clin. Pharmacol. Ther. (2002)
- Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem (M1) by rat jejunum in vitro. Molden, E., Christensen, H., Sund, R.B. Drug Metab. Dispos. (2000)